New research has uncovered how different people respond to sepsis based on their genetics, which could lead to the development of targeted therapies. The team from the Wellcome Sanger Institute, the University of Oxford, and collaborators built on their previous work that identified different subgroups of… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The selected news highlights this week report breakthrough findings from early phase research and… Read More
News round-up for 27-31 May by DDW Senior Digital Content Editor Diana Spencer. The selected news highlights this week report breakthrough findings from early phase research and development, mainly preclinical studies and Phase I clinical trials, including a drug that can prevent sepsis deaths, a microbiome based immuno-oncology… Read More
A new drug could prevent sepsis-related organ failure and death by restoring the health of a patient’s blood vessels. Researchers from The University of Queensland and the Queensland Children’s Hospital (QCH) have successfully tested the first-in-class drug in mice. Dr Mark Coulthard from UQ… Read More
University of Queensland (UQ) researchers have led a national study on the four main bacteria that cause sepsis, providing new targets for developing antibiotics. Professor Mark Walker and Professor Mark Schembri from UQ’s Institute for Molecular Bioscience, along with Dr Andre Mu from the University of… Read More
A pilot Phase IIa clinical trial evaluating Abionyx Pharma’s CER-001 as a treatment for septic patients at high risk of developing acute kidney injury (AKI) has met its primary endpoint. The RACERS study included 20 patients with gram-negative sepsis who were at high risk for acute kidney… Read More
